

# Reply: Medical science is based on facts and evidence

Citation for published version (APA):

Spronck, B., Avolio, A. P., Tan, I., Butlin, M., Reesink, K. D., & Delhaas, T. (2018). Reply: Medical science is based on facts and evidence. *Journal of Hypertension*, 36(4), 960-962.  
<https://doi.org/10.1097/HJH.0000000000001660>

## Document status and date:

Published: 01/04/2018

## DOI:

[10.1097/HJH.0000000000001660](https://doi.org/10.1097/HJH.0000000000001660)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

heterogeneous components [4]. Consequently, for such segments, it cannot be stated that  $CAVI_0$  is superior to CAVI. In fact, CAVI is deemed to be more suitable in actual human patients over the heart to ankle pathway. A recent study by Wohlfahrt *et al.* [5] of a total of 2160 white individuals shows that no clear benefit of  $CAVI_0$  was seen.

Soon, we will disclose some further aspects of CAVI, including the coefficients  $a$  and  $b$  contained in the CAVI formula, in a scientific publication.

Supplement:

$P_s$ : SBP,  $P_d$ : DBP,  $\Delta P$ :  $P_s - P_d$

$P_m$ : mid-pressure [defined as  $P_m = (P_s + P_d)/2$ ]

Then,  $P_s = P_m + \Delta P/2$ ,  $P_d = P_m - \Delta P/2$

$$\begin{aligned} \frac{\ln P_s - \ln P_d}{P_s - P_d} &= \frac{\ln(P_m + (\Delta P/2)) - \ln(P_m - (\Delta P/2))}{(P_m + (\Delta P/2)) - (P_m - (\Delta P/2))} \\ &= \frac{\ln(P_m + (\Delta P/2)) - \ln(P_m - (\Delta P/2))}{(P_m + (\Delta P/2)) - (P_m - (\Delta P/2))} \\ &= \frac{\ln(P_m + (\Delta P/2)) - \ln(P_m - (\Delta P/2))}{\Delta P} \\ &= \frac{\ln(P_m(1 + (\Delta P/2P_m))) - \ln(P_m(1 - (\Delta P/2P_m)))}{\Delta P} \\ &= \frac{\ln(1 + (\Delta P/2P_m)) + \ln P_m - \ln(1 - (\Delta P/2P_m)) - \ln P_m}{\Delta P} \\ &= \frac{\ln(1 + (\Delta P/2P_m)) + \ln P_m - \ln(1 - (\Delta P/2P_m)) - \ln P_m}{\Delta P} \\ &= \frac{1}{\Delta P} \left\{ \ln\left(1 + \frac{\Delta P}{2P_m}\right) - \ln\left(1 - \frac{\Delta P}{2P_m}\right) \right\} \end{aligned}$$

By applying the second order Maclaurin expansion to  $\ln(1 + \Delta P/(2P_m))$  and  $\ln(1 - \Delta P/(2P_m))$

$$\begin{aligned} &\approx \frac{1}{\Delta P} \left\{ \frac{\Delta P}{2P_m} - \frac{1}{2} \left( \frac{\Delta P}{2P_m} \right)^2 + \frac{\Delta P}{2P_m} + \frac{1}{2} \left( \frac{\Delta P}{2P_m} \right)^2 \right\} \\ &= \frac{1}{\Delta P} \left\{ \frac{\Delta P}{2P_m} - \frac{1}{2} \left( \frac{\Delta P}{2P_m} \right)^2 + \frac{\Delta P}{2P_m} + \frac{1}{2} \left( \frac{\Delta P}{2P_m} \right)^2 \right\} \\ &= \frac{1}{\Delta P} \left( \frac{\Delta P}{2P_m} + \frac{\Delta P}{2P_m} \right) \\ &= \frac{\Delta P}{\Delta P P_m} \\ &= \frac{\Delta P}{\Delta P P_m} \end{aligned}$$

## ACKNOWLEDGEMENTS

### Conflicts of interest

There are no conflicts of interest.

## REFERENCES

1. Spronck B, Avolio AP, Tan I, Butlin M, Reesink KD, Delhaas T. Reply: physics cannot be disputed. *J Hypertens* 2017; 35:1523–1525.

2. Shirai K, Shimizu K, Takata M, Suzuki K. Independency of the cardio-ankle vascular index from blood pressure at the time of measurement. *J Hypertens* 2017; 35:1521–1523.
3. Spronck B, Avolio AP, Tan I, Butlin M, Reesink KD, Delhaas T. Arterial stiffness index beta and cardio-ankle vascular index inherently depend on blood pressure but can be readily corrected. *J Hypertens* 2017; 35: 98–104.
4. Nichols WW, O'Rourke MF. Charalambos Vlachopoulou 2011: *McDonald's blood flow in arteries*, 6th edn. Hodder Arnolds 2011, 99–105.
5. Wohlfahrt P, Cifková R, Movsisyan N, Kunzová Š, Lešovský J, Homolka M, *et al.* Reference values of cardio-ankle vascular index in a random sample of a white population. *J Hypertens* 2017; 35:2238–2244.

Journal of Hypertension 2018, 36:957–965

<sup>a</sup>Mihama Hospital, Mihama-Ku, Chiba Prefecture, <sup>b</sup>Toyama Teishin Hospital, Toyama, Toyama Prefecture, <sup>c</sup>Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Science and <sup>d</sup>Cardiovascular Center, Sakura Hospital, Toho University, Chiba, Japan

Correspondence to Kohji Shirai, MD, PhD, Mihama Hospital, Mihama-Ku 261-0013, Chiba Prefecture, Japan. E-mail: kshirai@kb3.so-net.ne.jp

*J Hypertens* 36:957–965 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

DOI: 10.1097/HJH.0000000000001661

## Reply: Medical science is based on facts and evidence

Bart Spronck<sup>a,b,c</sup>, Alberto P. Avolio<sup>b</sup>,  
Isabella Tan<sup>b</sup>, Mark Butlin<sup>b</sup>, Koen D. Reesink<sup>a</sup>,  
and Tammo Delhaas<sup>a</sup>

We appreciate and read with great interest Shirai *et al.*'s addition [1] to the discussion involving our study on the pressure dependence of arterial stiffness index  $\beta$  and cardio-ankle vascular index (CAVI) [1–4]. In the present letter, we wish to point out that Shirai *et al.*'s [1] statement that CAVI represents arterial stiffness at the 'mid pressure' requires further consideration so as to clarify the underlying logical reasoning. Furthermore, we propose that the presented clinical data [1] neither support CAVI's use of 'mid pressure', nor provide evidence for or against CAVI's or  $CAVI_0$ 's acute blood pressure (BP) (in)dependence.

First, we appreciate that Shirai *et al.* acknowledge the mathematical correctness of stiffness index  $\beta_0$ . Stiffness index  $\beta$  has indeed been widely used with significant clinical impact. However, to our knowledge, no clinical study has directly compared  $\beta$  and  $\beta_0$  in terms of acute BP dependence. Therefore, we can only conclude that *theoretically* – but based on Hayashi's *experimental* findings of an exponential arterial pressure–diameter relationship [5] –  $\beta_0$  should show less pressure dependence than  $\beta$  [2].

Second, Shirai *et al.* introduce 'mid pressure' ( $P_m$ , not to be confused with *mean* BP) as a novel BP-related quantity. They show mathematically that CAVI's correction approximately corresponds to using  $P_m$  as a pressure reference point.

Subsequently and moreover, they state that  $P_m$  is the appropriate pressure metric to correct CAVI's underlying and essential measurement, the heart-to-ankle pulse wave velocity (haPWV). We respectfully disagree with this statement. haPWV is PWV measured by a foot-to-foot time delay. As we detailed in our previous letter [4] – and as already shown by Bramwell *et al.* [6] – a foot-to-foot PWV is, *by definition*, dependent on DBP [diastolic blood pressure ( $P_d$ )] [7–9]. It is the (diastolic) BP dependence of haPWV for which CAVI aims to correct. Therefore, the difference between CAVI and  $CAVI_0$  is not strictly a judgement on ‘...whether arterial stiffness is measured at the point of  $P_m$  or of  $P_d$ ’.  $CAVI_0$  uses the pressure at which the essential measurement of PWV is taken ( $P_d$ ), whereas CAVI uses a pressure ( $P_m$ ) that is approximately related to the pressure at which the measurement is taken without consideration for the theoretical or experimental evidence for the relationship of foot-to-foot measured PWV with  $P_d$ .

Shirai *et al.* [1] present Fig. 3 of their letter as evidence for their claim that haPWV depends on  $P_m$ . However, cross-sectional data cannot be reliably used to assess an acute relationship between PWV and BP [10] for reasons which we have previously discussed [11]. In fact, Shirai *et al.* themselves previously warned that ‘Several reports showed that CAVI is less dependent on BP than PWV, but these results *do not necessarily mean that CAVI is independent of BP at the time of measurement*’ [12]. Although a  $P$ -value is found wanting, the figure suggests that *between patients*, haPWV relates more strongly to  $P_m$  than to  $P_d$ . This is plausible and is probably due to patients with a higher  $P_m$  having an intrinsically stiffer wall. The latter is the reason that studies on reference values commonly report stiffness measures as a function of *mean* BP [13,14], which is closely related to the ‘mid pressure’ ( $P_m$ ) as introduced by Shirai *et al.* [1]. Mean BP is the pressure that is thought to be the one more closely related to arterial (hypertensive) *remodelling*. CAVI, however, aims to correct for the confounding effect of *acute* BP changes on PWV – not for intrinsic changes in arterial stiffness due to hypertensive arterial remodelling, which is the subject of interest rather than the confounder *per se*.

Third, we fully acknowledge that clinical data sets are sometimes small. However, a small data set should not be used to ‘prove’ that there is no change in a variable (CAVI in this case), a statement for which the data in this example [15] was statistically underpowered (footnote on p. 108 in [11]). Nevertheless, we would like to compliment Shirai *et al.* [15] with the design of this study, which – with a larger number of patients – would be appropriate to investigate the *acute* BP dependence of CAVI and  $CAVI_0$ . The (large) epidemiological dataset that Shirai *et al.* refer to (Fig. 2 in [3]) on the contrary only illustrates the *cross-sectional* relationship of CAVI/ $CAVI_0$  and age/hypertension.

In conclusion, we propose that there is no need to introduce ‘mid pressure’ as yet another BP-related quantity, and we hold that the clinical data provided by Shirai *et al.* cannot be used to fully assess the acute BP (in)dependence of CAVI or  $CAVI_0$ . We would like to emphasise that we have no issue at all with the use of CAVI or the use of the VaSera device (Fukuda Denshi Co., Ltd., Tokyo, Japan). Rather, our

article [2] aimed to propose slightly modified stiffness indices –  $\beta_0$  and  $CAVI_0$  – that (unlike  $\beta$  and CAVI) are theoretically independent of BP, but similarly easy to calculate and therefore still clinically applicable.  $CAVI_0$  can be directly calculated from existing CAVI values or from underlying variables provided by the VaSera system [16] – the  $CAVI_0$  equation could indeed be easily implemented into the VaSera system itself. We look forward to the publication announced by Shirai *et al.* on further aspects of CAVI.

## ACKNOWLEDGEMENTS

The current study was supported by an Endeavour Research Fellowship awarded by the Australian Government to B.S.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Shirai K, Takata M, Takahara A, Shimizu K. Medical Science is based on evidence (answer to Spronck *et al.*'s refutation: physics cannot be disputed). *J Hypertens* 2018; 36:958–960.
- Spronck B, Avolio AP, Tan I, Butlin M, Reesink KD, Delhaas T. Arterial stiffness index beta and cardio-ankle vascular index inherently depend on blood pressure but can be readily corrected. *J Hypertens* 2017; 35:98–104.
- Shirai K, Shimizu K, Takata M, Suzuki K. Independence of the cardio-ankle vascular index from blood pressure at the time of measurement. *J Hypertens* 2017; 35:1521–1523.
- Spronck B, Avolio AP, Tan I, Butlin M, Reesink KD, Delhaas T. Reply: physics cannot be disputed. *J Hypertens* 2017; 35:1523–1525.
- Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. *J Biomech* 1980; 13:175–184.
- Bramwell JC, McDowall RJS, McSwiney BA. The variation of arterial elasticity with blood pressure in man (Part I). *R Soc Lond Proc Ser B* 1923; 94:450–454.
- Nye ER. The effect of blood pressure alteration on the pulse wave velocity. *Br Heart J* 1964; 26:261–265.
- Nichols W, O'Rourke M, Vlachopoulos C. *McDonald's blood flow in arteries: theoretical, experimental and clinical principles*. London, UK: CRC Press; 2011.
- Gao M, Cheng H-M, Sung S-H, Chen C-H, Olivier NB, Mukkamala R. Estimation of pulse transit time as a function of blood pressure using a nonlinear arterial tube-load model. *IEEE Trans Biomed Eng* 2017; 64:1524–1534.
- Benetos A. Assessment of arterial stiffness in an older population: the interest of the cardio-ankle vascular index (CAVI). *Eur Heart J Suppl* 2017; 19:B11–B16.
- Spronck B, Delhaas T, Butlin M, Reesink KD, Avolio AP. Options for dealing with pressure dependence of pulse wave velocity as a measure of arterial stiffness: an update of cardio-ankle vascular index (CAVI) and  $CAVI_0$ . *Pulse* 2017; 5:106–114.
- Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, *et al.* Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. *J Atheroscler Thromb* 2011; 18:924–938.
- Wohlfahrt P, Cifkova R, Movsisyan N, Kunzova S, Lesovsky J, Homolka M, *et al.* Reference values of cardio-ankle vascular index in a random sample of a white population. *J Hypertens* 2017; 35:2238–2244.
- Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. *Eur Heart J* 2010; 31:2338–2350.
- Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, *et al.* Contradictory effects of beta1- and alpha1-adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) – CAVI is independent of blood pressure. *J Atheroscler Thromb* 2011; 18: 49–55.

16. Spronck B, Mestanić M, Tonhajzerova I, Jurko A, Jurko T, Avolio AP, Butlin M. Direct means of obtaining CAVI0 – a corrected cardio-ankle vascular stiffness index (CAVI)-from conventional CAVI measurements or their underlying variables. *Physiol Meas* 2017; 38: N128–N137.

Journal of Hypertension 2018, 36:957–965

<sup>a</sup>Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands, <sup>b</sup>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia and <sup>c</sup>Department of Biomedical Engineering, School of Engineering & Applied Science, Yale University, New Haven, Connecticut, USA

Correspondence to Bart Spronck, PhD, Department of Biomedical Engineering, School of Engineering & Applied Science, Yale University, 55 Prospect Street, New Haven, CT 06511, USA. Tel: +1 203 432 6678; e-mail: bart.spronck@yale.edu

J Hypertens 36:957–965 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

DOI:10.1097/HJH.0000000000001660

## Facebook advertising for disseminating hypertension knowledge to older Chinese adults

Phillip H. Dunn and Benjamin K.P. Woo

With great interest, we read the original article by Nash *et al.* [1] discussing the use of Facebook advertising for the recruitment of patients into a blood pressure clinical trial in Australia. The study was the first to determine whether Facebook may be a useful tool to enhance blood pressure clinical trial recruitment and to ascertain the effectiveness of recruiting middle to older aged study participants through intermittent broadcast of Facebook advertisements. Participant recruitment successfully increased at two of three sites where Nash's team conducted the study. The study also found that Facebook advertising could be useful in recruiting a cohort of older participants typical of cardiovascular-related clinical trials [1]. Nevertheless, the authors suggest that the success of Facebook advertising may be location-dependent. To expand upon the study, we demonstrated similar results in a Facebook advertising for disseminating hypertension knowledge to older Chinese adults.

Health disparities facing the Chinese community can be reduced through effective health education and outreach [2]. Although e-health education has enormous potential, in-person workshops are more effective at disseminating knowledge to target older Chinese-speaking population [3,4]. In our study, we created a Facebook campaign to raise awareness and knowledge on hypertension in the Chinese community. Our advertisement included a video link, a five-character title and 26-character text body both in traditional written Chinese. Advertisements were able to be targeted towards Chinese-speaking men and women aged older than

44 years as these details were included as part of registering for Facebook. We then separated the participants into three age brackets: (1) 45–54 years, (2) 55–64 years, or (3) 65 years or older. Our study tracked the click-through rate (clicks/impressions), as defined by the ratio of users who clicked on the video link to the number of total Facebook users who viewed the hypertension awareness and knowledge advertisements. The click-through rates for the three age groups were 3.57, 8.04, and 14.71% for the age brackets 45–54 years, 55–64 years, and 65 years or older, respectively.

Our results lend support to the Nash *et al.* [1] study. Facebook advertising could be useful in outreaching to older adults in different locations. These results encourage using Facebook advertisements, in Australian or Chinese older adults, to increase participations in hypertension health-related studies. Although Facebook was successful in recruiting a cohort of participants in an older age bracket typical of developing cardiovascular diseases, our study showed that the advertisement was most effective in the 65 years or older group, with a click-through rate of 14.71%. Nevertheless, success in recruiting participants in further hypertension education may not translate into success in clinical trial recruitment. Future prospective studies should be designed to determine the effects of Facebook advertising on recruiting older Chinese for blood pressure clinical trials. Given the limited sources of language and culturally appropriate health information for older Chinese [5], future studies should also be designed to determine how to effectively promote quality e-health information online.

### ACKNOWLEDGEMENTS

#### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

- Nash EL, Gilroy D, Srikusalanukul W, Abhayaratna WP, Stanton T, Mitchell G, *et al.* Facebook advertising for participant recruitment into a blood pressure clinical trial. *J Hypertens* 2017; 35:2527–2531.
- Woo BK. Dementia health promotion for Chinese Americans. *Cureus* 2017; 9:e1411.
- Zheng X, Woo BK. E-mental health in ethnic minority: a comparison of youtube and talk-based educational workshops in dementia. *Asian J Psychiatr* 2017; 25:246–248.
- Zheng X, Woo BK. Exploring the impact of a culturally tailored short film in modifying dementia stigma among Chinese Americans: a pilot study. *Acad Psychiatry* 2016; 40:372–374.
- Tsiang JT, Woo BK. Comparison of online dementia information in Chinese and in English languages. *Cureus* 2017; 9:e1808.

Journal of Hypertension 2018, 36:957–965

Asian Pacific Health Corps, University of California, Los Angeles, California, USA

Correspondence to Benjamin K.P. Woo, MD, Department of Psychiatry and Biobehavioral Sciences, Olive View – UCLA Medical Center, Sylmar, CA 91342, United States. Tel: +1 747 210 4433; fax: +1 747 210 3554; e-mail: bkpwoo@gmail.com

J Hypertens 36:957–965 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

DOI:10.1097/HJH.0000000000001660